Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS

International Reviews of Immunology

Volumn 24, Issue 5-6, 2005, Pages 447-477

  Offner, Halina ^a,c   Vandenbark, Arthur A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Estrogen; Experimental autoimmune encephalomyelitis; FoxP3; Multiple sclerosis; T cell receptor; Therapy

Indexed keywords

CD4 ANTIGEN; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; INTERLEUKIN 2 RECEPTOR ALPHA; PEPTIDE; PLACEBO; T LYMPHOCYTE RECEPTOR PEPTIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VACCINE;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALOMYELITIS; CELL DENSITY; CELL SPECIFICITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET CELL; THIRD TRIMESTER PREGNANCY; VACCINATION;

EID: 28744456154     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180500371462     Document Type: Review

References (81)

1. L. Steinman, Autoimmune disease, Sci. Am., 169: 106, 1993.
2. R. Martin, H.F. McFarland, and D.E. McFarlin, Immunological aspects of demyelinating diseases, Ann. Rev. Immunol., 10: 153-187, 1992.
3. + regulatory T cells, Nat. Immunol., 4: 330-336, 2003.
4. + T regulatory cells, Nat. Immunol., 4: 337-342, 2003.
5. E. Cambineri, T.R. Torgerson, and H.D. Ochs, Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis, Curr. Opin. Rheumatol., 15: 340-345, 2003.
6. L. Steinman, Multiple sclerosis: A two stage disease, Nat. Immunol., 2: 762-765, 2001.
7. S. Sakaguchi, Regulatory T cells: Key controllers of immunological self-tolerance, Cell, 101: 455-458, 2000.
8. L. Van Parijs and A.K. Abbas, Homeostasis and self-tolerance in the immune system: Turning lymphocytes off, Science, 280: 243-246, 1998.
9. T. Olsson, Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis, Immunol. Rev., 144: 245-248, 1995.
10. C.S. Raine and L.C. Scheinberg, On the immunopathology of plaque development and repair in multiple sclerosis, J. Neuroimmunol., 20: 189-194, 1988.
11. P.V. Lehmann, T. Forsthuber, A. Miller, and E.E. Sercarz, Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen, Nature, 358: 155-157, 1992.
12. S.D. Miller and W.J. Karpus, The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases, Immunol. Today, 15: 356-361, 1994.
13. G.J. Hammerling, G. Schonrich, I. Ferber, and B. Arnold, Peripheral tolerance as a multi-step mechanism, Immunol. Rev., 93-104, 1993.
14. T.R. Mossman and R.L. Coffman, Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 7: 145-150, 1989.
15. V.K. Kuchroo, M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher, B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy, Cell, 80: 707-712, 1995.
16. D.J. Cua, D.R. Hinton, and S.A. Stohlman, Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease, J. Immunol., 155: 4052-4061, 1995.
17. L. Santambrogio, G.M. Hochwald, B. Saxena, C.H. Leu, J.E. Martz, J.A. Carlino, N.H. Ruddle, M.A. Palladino, L.I. Gold, and G.J. Thorbecke, Studies on the mechanisms by which transforming growth factor beta (TGF-β) protects against allergic encephalomyelitis. Antagonism between TGF-β and tumor necrosis factor, J. Immunol., 151: 1116-1127, 1997.
18. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis, Nature, 389: 737-742, 1997.
19. + suppresser T-cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice, J. Autoimmunity, 9: 331-339, 1996.
20. K.J. Maloy and F. Powrie, Regulatory T cells in the control of immune pathology, Nature Immunol., 2: 816-822, 2001.
21. M.G. Roncarolo and M.K. Levings, The role of different subsets of T regulatory cells in controlling autoimmunity, Curr. Opin. Immunol., 12: 676-683, 2000.
22. E.M. Shevach, Regulatory T cells in autoimmunity, Ann. Rev. Immunol., 18: 423-449, 2000.
23. J.T. Kaufman and J. Tian, Attenuation of Inducible Th2 Immunity with Autoimmune Disease Progression, J. Immunol., 161: 5399-5403, 1998.
24. S. Hori, T. Nomura, and S. Sakaguchi, Control of regulatory T-cell development by the transcription factor Foxp3, Science, 299: 1057-1061, 2003.
25. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmne encephalomyelitis, J. Immunol., 169: 4712-4716, 2002.
26. C.C. Whitacre, Sex differences in autoimmune disease, Nature Immunol., 2: 777-780, 2001.
27. C. Confavreux, M. Huchinson, M.M. Hours, P. Corinovis-Tourniaire, and T. Moreau, Rate of pregnancy-related relapse in multiple sclerosis, N. Engl. J. Med., 339: 285-291, 1998.
28. S. Vukusic, M. Hutchinson, M. Hours, T. Moreau, P. Cortinovis-Tourniaire, P. Adeleine, and C. Canfavreux, Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse, Brain, 127: 1353-1360, 2004, [erratum appears in Brain, 127(Pt 8):1912].
29. H. Offner, Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis, J. Neurosci. Res., 78: 603-624, 2004.
30. + regulatory T-cell compartment, J. Immunol., 173: 2227-2230, 2004.
31. V.R. Aluvihare, M. Kallikourdis, and A.G. Betz, Regulatory T cells mediate maternal tolerance to the fetus, Nat. Immunol., 5: 266-271, 2004.
32. + regulatory T-cell subset, Immunol., 112: 38-42, 2004.
33. M.J. Polanczyk, C. Hopke, J. Huan, A.A. Vandenbark, and H. Offner, Enhanced FoxP3 expansion and Treg cell function in pregnant and estrogen-treated mice, J. Neuroimmunol., 11: 1-10, 2005.
34. B.A. Liu Hy, A. Matejuk, A. Ito, A. Zamora, J. Dwyer, A.A. Vandenbark, and H. Offner, Estrogen inhibition of EAE may involve differential effects on mature vs. immature dendritic cells, J. Neurosci. Res., 70: 238-248, 2002.
35. H. Offner, K. Adlard, A. Zamora, and A.A. Vandenbark, Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis, J. Clin. Invest., 105: 1465-1472, 2000.
36. B.F. Bebo, A. Fyfe-Johnson, K. Adlard, A.G. Beam, A.A. Vandenbark, and H. Offner, Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains, J. Immunol., 166: 2080-2089, 2001.
37. A. Matejuk, K. Adlard, A. Zamora, M. Silverman, A.A. Vandenbark, and H. Offner, 17β-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental encephalomyelitis, J. Neurosci. Res., 65: 529-542, 2001.
38. A. Ito, J.B.F. Bebo, A. Matejuk, A. Zamora, M. Silverman, A. Fyfe-Johnson, and H. Offner, Estrogen treatment down-regulates TNF-α; production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice, J. Immunol., 167: 542-552, 2001.
39. W. Gilmore, L.P. Weiner, and J. Correale, Effect of estradiol on cytokine secretion by proteolipid protein-specific T-cell clones isolated from multiple sclerosis patients and normal control subjects, J. Immunol., 158: 446-451, 1997.
40. M.P. Piccinni, M.G. Giudizi, R. Bisgiotti, L. Betoni, L. Giannarini, S. Sampognaro, P. Parronchi, R. Manetti, F. Annunziato, C. Livi, et al., Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones, J. Immunol., 155: 128-136, 1995.
41. A. Matejuk, J. Dwyer, A. Zamora, A.A. Vandenbark, and H. Offner, Evaluation of the effects of 17B-estradiol (17B-E2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray, Endocrinol., 143: 313-319, 2002.
42. M. Polanczyk, A. Zamora, S. Subramanian, A. Matejuk, D.L. Hess, E.P. Blankenhorn, C. Teuscher, A.A. Vandenbark, and H. Offner, The protective effect of 17B-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-α, Am. J. Pathol., 163: 1599-1605, 2003.
43. M.J. Polanczyk, R.E. Jones, S. Subramanian, M. Afentoulis, C. Rich, M. Zakroczymski, P. Cooke, A.A. Vandenbark, and H. Offner, T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis, Am. J. Pathol., 165: 2069-2077, 2004.
44. G.C. Furtado, D. Olivares-Villagomez, M.A.C. Lafaille, A.K. Wensky, J. Latkowski, and J.J. Lafaille, Regulatory T cells in spontaneous autoimmune encephalomyelitis, Immunol. Rev., 182: 122-134, 2001.
45. S. Subramanian, A. Matejuk, A. Zamora, A.A. Vandenbark, and H. Offner, Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system, J. Immunol., 170: 1548-1555, 2003.
46. I.R. Cohen and D.B. Young, Autoimmunity, microbial immunity and the immunological homunculus, Immunol. Today, 12: 105-110, 1991.
47. A.A. Vandenbark, G. Hashim, and H. Offner, Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis, Nature, 341: 541-544, 1989.
48. M.D. Howell, S.T. Winters, T. Olee, H.C. Powell, D.J. Carlo, and S.W. Brostoff, Vaccination against experimental allergic encephalomyelitis with T-cell receptor peptides, Science, 246: 668-670, 1989.
49. H. Jiang, E. Sercarz, D. Nitecki, and B. Pernis, The problem of presentation of T cell receptor peptides by activated T cells, Ann. N. Y. Acad. Sci., 636: 28-32, 1991.
50. A.A. Vandenbark, G.A. Hashim, and H. Offner, T-cell receptor peptides in treatment of autoimmune disease: rationale and potential, J. Neurosci. Res., 43: 391-402, 1996.
51. H. Offner, G.A. Hashim, and A.A. Vandenbark, T-cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, Science, 251: 430-432, 1991.
52. V. Kumar, E. Coulsell, B. Ober, G. Hubbard, E. Sercarz, and E.S. Ward, Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis, J. Immunol., 159: 5150-5156, 1997.
53. M. Vainiene, B. Celnik, G.A. Hashim, A.A. Vandenbark, and H. Offner, Natural immunodominant and EAE-protective determinants within the Lewis rat V 8.2 sequence include CDR2 and framework 3 idiotopes, J. Neurosci. Res., 43: 137-145, 1996.
54. V. Kumar, R. Tabibiazar, H.M. Geysen, and E. Sercarz, Immunodominant framework region 3 peptide from TCR VB8.2 chain controls murine experimental autoimmune encephalomyelitis, J. Immunol., 154: 1941-1950, 1995.
55. H. Offner, K. Adlard, B.F. Bebo, J. Schuster, G.G. Burrows, A.C. Buenafe, and A.A. Vandenbark, Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 mice, J. Immunol., 161: 2178-2186, 1998.
56. H. Offner, R. Jacobs, B.F. Bebo, and A.A. Vandenbark, Treatments targeting the TCR: Effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of MBP-specific T cells, Springer Sem. Immunopathol., 21: 77-90, 1999.
57. + TCR-specific T cells involves IL-4, IL-10 and IFN-gamma, Autoimmunity, 31: 237-248, 1999.
58. D.A. Hafler, M.G. Saadeh, V.K. Kuchroo, E. Milford, and L. Steinman, TCR usage in human and experimental demyelinating disease, Immunol. Today, 17: 152-159, 1996.
59. D.N. Bourdette, R.H. Whitham, Y.K. Chou, W.J. Morrison, J. Atherton, C. Kenny, D. Liefeld, G.A. Hashim, H. Offner, and A.A. Vandenbark, Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V 5.2 and V 6.1 CDR2 peptides, J. Immunol., 152: 2510-2519, 1994.
60. D.N. Bourdette, Y.K. Chou, R.H. Whitham, J. Buckner, H.J. Kwon, G.T. Nepom, A. Buenafe, S.A. Cooper, M. Allegretta, G.A. Hashim, et al., Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity determining region 2 peptides from disease-associated T cell receptor BV genes, J. Immunol., 161: 1034-1044, 1998.
61. D.P. Gold, R.A. Smith, A.B. Golding, E.E. Morgan, T. Dafashy, J. Nelson, L. Smith, J. Diveley, J.A. Laxer, S.P. Richieri, et al., Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide, J. Neuroimmunol., 76: 29-35, 1997.
62. A.A. Vandenbark, Y.K. Chou, R. Whitham, M. Mass, A. Buenafe, D. Liefeld, D. Kavanagh, S. Cooper, G.A. Hashim, H. Offner, et al., Treatment of multiple sclerosis with T cell receptor peptides: Results of a double-blind pilot trial, Nat. Med., 2: 1109-1115, 1996.
63. L.W. Moreland, E.E. Morgan, T.C. Adamson, Z. Fronek, L.H. Calabrese, J.M. Cash, J.A. Markenson, A.K. Matsumoto, J. Bathon, E.L. Matteson, et al., T cell receptor peptide vaccination in rheumatoid arthritis. A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides, Arthritis Rheuma., 41: 1919-1929, 1998.
64. A.C. Buenafe, R.C. Tsu, B.F. Bebo, A.A. Vandenbark, and H. Offner, Myelin basic protein-specific and TCR VB8.2-specific T-cell lines from TCR VB8.2 transgenic mice utilize the same Vα and Vβ genes: Specificity associated with the Vβ CDR3-Jα region, J. Neurosci. Res., 47: 489-499, 1997.
65. B. Siklodi, R. Jacobs, G.G. Burrows, A.A. Vandenbark, and H. Offner, Neonatal exposure of TCR BV8S2 transgenic mice to recombinant TCR BV8S2 results in reduced T cell proliferation and elevated antibody response to BV8S2 and increased severity of EAE, J. Neurosci. Res., 52: 750-756, 1998.
66. A. Matejuk, A.A. Vandenbark, C. Burrows, B.F. Bebo Jr., and H. Offner, Reduced chemokine and chemokine receptor expression in spinal cords of TCR BV8S2 transgenic mice protected against experimental autoimmune encephalomyelitis with BV8S2 protein, J. Immunol., 164: 3924-3931, 2000.
67. A.A. Vandenbark, N. Culbertson, T. Finn, D. Barnes, A. Buenafe, G.G. Burrows, S. Law, Y.K. Chou, and H. Offner, Human TCR as antigen: Homologies and potentially cross-reactive HLA-DR2-restricted epitopes within the AV and BV CDR2 loops, Crit. Rev. Immunol., 20: 57-83, 2000.
68. + T cells for self-T cell receptor determinants, J. Neurosci. Res., 76: 129-140, 2004.
69. A.A. Vandenbark, T. Finn, D. Barnes, N. Culbertson, Y.K. Chou, K. Hicks, A. Bakke, M. Mass, R. Whitham, and D. Bourdette, Diminished frequency of IL-10 secreting, TCR peptide-reactive T-cells in multiple sclerosis patients may allow expansion of activated memory T-cells bearing the cognate BV gene, J. Neurosci. Res., 66: 171-176, 2001.
70. G.G. Burrows, Y.K. Chou, C. Wang, J.W. Chang, T.P. Finn, N.E. Culbertson, J. Kim, D.N. Bourdette, D.A. Lewinsohn, et al., Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells, J. Immunol., 167: 4386-4395, 2001.
71. + Treg cells reveals an age-dependent loss of suppressive activity, J. Neurosci. Res., 74: 296-308, 2003.
72. J. Huan, N. Culbertson, L. Spencer, R. Bartholomew, G.G. Burrows, Y. Chou, D. Bourdette, S.F. Ziegler, H. Offner, and A.A. Vandenbark, Decreased FOXP3 levels in multiple sclerosis patients, J. Neurosci. Res., 81: 45-52, 2005.
73. + regulatory T cells in patients with multiple sclerosis, J. Exp. Med., 199: 971-979, 2004.
74. A.A. Vandenbark, E. Morgan, D. Bourdette, R. Whitham, D. Gold, R. Bartholomew, D. Carlo, G. Hashim, and H. Offner, TCR peptide therapy in human autoimmune diseases, Neurochem. Res., 26: 713-730, 2001.
75. + Treg cells, Curr. Drug Targets Inflamma. Allergy, 4: 217-229, 2005.
76. B.L. Kotzin, S. Karuturi, Y.K. Chou, J. Lafferty, J.M. Forrester, M. Better, G.E. Nedwin, H. Offner, and A.A. Vandenbark, Preferential T cell receptor β-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis, Proc. Natl. Acad. Sci. U.S.A., 88: 9161-9165, 1991.
77. H. Offner and A.A. Vandenbark, T cell receptor V genes in multiple sclerosis: Increased use of TCRAV8 and TCRBV5 in MBP-specific clones, Intern. Rev. Immunol., 18: 9-36, 1999.
78. A.A. Vandenbark, D.N. Bourdette, and T.T.P.V.S. Group, T cell receptor peptide vaccination in multiple sclerosis: Results from a multicenter, double-blind, placebo controlled phase I/II trial, Neurology, 56(Suppl. 3): A75, 2001.
79. Y.K. Chou, W.J. Morrison, A.D. Weinberg, R. Dedrick, R. Whitham, D.N. Bourdette, G. Hashim, H. Offner, and A.A. Vandenbark, Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides, J. Immunol., 152: 2520-2529, 1994.
80. Y.K. Chou, A.D. Weinberg, A. Buenafe, D.N. Bourdette, R. Whitham, J.A.R. Kaleeba, I.F. Robey, D.G. Kavanagh, H. Offner, and A.A. Vandenbark, MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR VB CDR2 peptides: Comparison with myelin basic protein-specific T cells, J. Neurosci. Res., 45: 838-851, 1996.
81. D.N. Bourdette, E. Edmonds, C. Smith, J.D. Bowen, C.R.G. Guttmann, Z.P. Nagy, J. Simon, R. Whitham, J. Lovera, V. Yadav, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis, Mult. Scler., (in press), 2005.